How much does Etrasimod cost in China? Latest selling price in 2025

Etrasimod is a novel sphingosine-1-phosphate (S1P) receptor modulator, primarily used to treat adult patients with moderately to severely active ulcerative colitis (UC). Ulcerative colitis is a chronic inflammatory bowel disease characterized by chronic inflammation and ulceration of the colon, resulting in significant decreases in quality of life and physical health consequences for patients. Itramod helps reduce intestinal inflammation and improve clinical symptoms by modulating S1P receptors.

In the treatment of ulcerative colitis, clinical trial results of itrimod have shown good efficacy and safety. After receiving treatment, the patients' inflammatory indicators were significantly improved and the clinical remission rate was also improved. In addition, the oral administration method of the drug makes it easier for patients to accept and tolerate it. Compared with some biological agents that require injection or intravenous infusion, Itrimod provides a more convenient medication option. Nonetheless, the use of istrimod should still be done under the guidance of a physician, as its potential side effects and indications require professional evaluation.

Currently, itridimod is not yet available in China, so domestic patients cannot obtain the drug through formal channels. At the same time, because it is not covered by medical insurance, patients have a heavy financial burden to purchase it on their own. In the international market, the original version of itramod has been launched in Europe, the United States and other places, with prices generally ranging from RMB 10,000 to RMB 30,000. The specific price is affected by various factors such as region, drug supply chain, and insurance policy. At this stage, there are no generic drugs of itramod on the market, which further limits patients’ medication choices and reduces their economic burden.

In summary, as an emerging drug for the treatment of ulcerative colitis, itridimod’s unique mechanism of action and good clinical effects provide new hope for patients. However, due to its high price and the fact that it is not on the market in China, patients must fully consider their own financial situation and health needs when choosing treatment options.

Reference materials:https://www.drugs.com/mtm/etrasimod.html